Expanding Medical Marijuana Access in Canada: Considerations for the Rheumatologist

Fitzcharles, Mary‐Ann; Jamal, Shahin

doi:10.3899/jrheum.131514

Cited by 10 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Canada , the Marihuana Medical Access Regulations (MMAR) was enacted in 2001, which permitted the use of MM for severe illnesses upon approval by Health Canada. In 2014, the new Marihuana for Medical Purposes Regulations was enacted to replace the MMAR, enabling medical practitioners to prescribe MM regardless of patient’s medical conditions or failure of conventional treatments (Fitzcharles and Jamal, 2015). In Israel, individual patients can obtain a MM license after the Medical Cannabis Unit of the Ministry of Health approves a specialist’s recommendation (Sznitman and Lewis, 2015).…”

Section: Introductionmentioning

confidence: 99%

Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review

Park

2017

Drug and Alcohol Dependence

137

View full text Add to dashboard Cite

Background The use of marijuana for medical purposes is now legal in some U.S. states and other jurisdictions, such as Canada, and Israel. Despite the widespread legalization of medical marijuana globally, there is limited information on patterns and correlates of medical marijuana use (MMU). We conducted a literature review to assess prevalence, reasons, perceived effects, and correlates of MMU among adolescents and adults. Methods We searched peer-reviewed articles in English between January 1996 and August 2016 from several databases (PubMed, Google Scholar, Embase, CINAHL, and PsycINFO) using different combinations of keywords. Results A total of 25 articles met the inclusion criteria. In the U.S., national survey estimates of prescribed MMU was 1.1% among 12th graders and 17% among adults who reported past-year marijuana use. The reported prevalence of prescribed MMU ranged from <1.7% in Israeli cancer patients to 17.4% in American health care patients. The reported prevalence of self-medication with marijuana ranged from 15% in Canadian patients with chronic pain to 30% in British patients with multiple sclerosis. Pain was the most frequently endorsed reason for use. MMU appeared to provide symptom relief for a range of pain conditions, sleep disturbance, and anxiety symptoms, but it did not appear to provide sufficient relief of cluster headache symptoms. Non-medical marijuana use was a common factor associated with MMU across studies. Conclusion Either MMU or self-medication with marijuana was common, mainly due to pain management. Additional research is needed to evaluate temporal and causal associations of non-medical marijuana use with MMU.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review

Park

2017

Drug and Alcohol Dependence

137

View full text Add to dashboard Cite

show abstract

“…Diversos artículos de investigación señalan el UMC como seguro y eficaz para muchos pacientes con dolor crónico (Aggarwal et al, 2014;Brunt, Van Genugten, Höner-Snoeken, Van De Velde, & Niesink, 2014;Fitzcharles & Jamal, 2015;Maida & Corban, 2017;Piper et al, 2017;Shah, Craner, & Cunningham, 2017;Webb & Webb, 2014). Se le considera una alternativa para aquellas personas que reciben terapias analgésicas prolongadas con múltiples efectos adversos, como paliativo del dolor en el cáncer avanzado y para las molestias asociadas con la quimioterapia por su efecto antiemético, siendo más seguro que ciertos medicamentos convencionales (Avello, Pastene, Fernández, & Córdova, 2017;Braun et al, 2017;Stinson & De Angelis, 2017;Waissengrin, Urban, Leshem, Garty, & Wolf, 2015).…”

Section: Beneficios Del Umcunclassified

Uso medicinal de cannabis: una revisión de la evidencia

et al. 2019

View full text Add to dashboard Cite

Este estudio pretende reportar la evidencia actual sobre el uso medicinal de cannabis existente en la base de datos Scopus. Se llevó a cabo una revisión sistemática de las publicaciones científicas, entre el periodo 2013-2017, disponibles en Scopus sobre el uso medicinal de cannabis. Estados Unidos es el país con mayor cantidad de publicaciones, seguido de Canadá e Israel; existiendo un aumento progresivo y constante de la evidencia entre los años 2013 y 2017. Los contenidos de las publicaciones versan sobre efectos beneficiosos y adversos para la salud, consecuencias de la legislación del cannabis y su asociación con diversas variables. Existe una falta de estudios en uso medicinal de cannabis respecto a tratamientos y enfermedades, su estandarización, vías de administración y dosis, dando cuenta de la necesidad de un volumen mayor de investigaciones al respecto.

show abstract